238 related articles for article (PubMed ID: 37719724)
21. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J
Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
24. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
25. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
Lehtinen M; Söderlund-Strand A; Vänskä S; Luostarinen T; Eriksson T; Natunen K; Apter D; Baussano I; Harjula K; Hokkanen M; Kuortti M; Palmroth J; Petäjä T; Pukkala E; Rekonen S; Siitari-Mattila M; Surcel HM; Tuomivaara L; Paavonen J; Dillner J; Dubin G; Garnett G
Int J Cancer; 2018 Mar; 142(5):949-958. PubMed ID: 29055031
[TBL] [Abstract][Full Text] [Related]
26. Impact of HPV vaccination with Gardasil® in Switzerland.
Jacot-Guillarmod M; Pasquier J; Greub G; Bongiovanni M; Achtari C; Sahli R
BMC Infect Dis; 2017 Dec; 17(1):790. PubMed ID: 29273004
[TBL] [Abstract][Full Text] [Related]
27. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
Cornall AM; Saville M; Pyman J; Callegari ET; Tan FH; Brotherton JML; Malloy MJ; Tabrizi SN; Wrede CD; Garland SM;
Vaccine; 2020 Sep; 38(40):6304-6311. PubMed ID: 32736938
[TBL] [Abstract][Full Text] [Related]
28. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
29. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
30. Impact of HPV vaccination on HPV-related oral infections.
Gheit T; Muwonge R; Lucas E; Galati L; Anantharaman D; McKay-Chopin S; Malvi SG; Jayant K; Joshi S; Esmy PO; Pillai MR; Basu P; Sankaranarayanan R; Tommasino M
Oral Oncol; 2023 Jan; 136():106244. PubMed ID: 36402055
[TBL] [Abstract][Full Text] [Related]
31. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
[TBL] [Abstract][Full Text] [Related]
33. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.
Wang R; Guo XL; Wisman GB; Schuuring E; Wang WF; Zeng ZY; Zhu H; Wu SW
BMC Infect Dis; 2015 Jul; 15():257. PubMed ID: 26142044
[TBL] [Abstract][Full Text] [Related]
34. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
35. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique.
Edna Omar V; Orvalho A; Nália I; Kaliff M; Lillsunde-Larsson G; Ramqvist T; Nilsson C; Falk K; Nafissa O; Ilesh Vindorai J; Andersson S
BMJ Open; 2017 Jul; 7(7):e015653. PubMed ID: 28716790
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.
Debrah O; Agyemang-Yeboah F; Donkoh ET; Asmah RH
BMC Womens Health; 2021 Oct; 21(1):372. PubMed ID: 34702246
[TBL] [Abstract][Full Text] [Related]
38. Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.
Chow EPF; Fairley CK; Zou H; Wigan R; Garland SM; Cornall AM; Atchison S; Tabrizi SN; Chen MY
Clin Infect Dis; 2022 Aug; 75(2):323-329. PubMed ID: 34971362
[TBL] [Abstract][Full Text] [Related]
39. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
40. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]